Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)

This publication has 22 references indexed in Scilit:

• Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials
  Clinical Therapeutics, 2000
• N-Acetylcysteine Reduces the Exacerbation Rate in Patients with Moderate to Severe COPD
  Respiration, 1999
• Iodinated Glycerol Has No Effect on Pulmonary Function, Symptom Score, or Sputum Properties in Patients With Stable Chronic Bronchitis
  Chest, 1996
• Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force
  European Respiratory Journal, 1995
• Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
  Respiratory Medicine, 1994
• The National Mucolytic Study
  Chest, 1990
• Oral fabrol (oral N-acetylcysteine) in chronic bronchitis
  Respiratory Medicine, 1987
• Ambroxol for the Prevention of Chronic Bronchitis Exacerbations: Long-Term Multicenter Trial
  Respiration, 1987
• Ambroxol and Simple Chronic Bronchitis. Effects on Subjective Symptoms and Ventilatory Function
  Respiration, 1987
• Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee.
  Thorax, 1985